Findings of Research Misconduct, 32123 [07-2866]
Download as PDF
<![CDATA[
Federal Register / Vol. 72, No. 111 / Monday, June 11, 2007 / Notices
People 2010: Volumes I and II can be
purchased by calling (202) 512–1800
(cost $70.00 for printed version; $20.00
for CD–ROM). Another reference is the
Healthy People 2010 Final Review—
2001.
For one free copy of the Healthy
People 2010, contact: The National
Center for Health Statistics, Division of
Data Services, 3311 Toledo Road,
Hyattsville, MD 20782, or by telephone
at (301) 458–4636. Ask for HHS
Publication No. (PHS) 99–1256. This
document may also be downloaded
from: https://www.healthypeople.gov.
3. Definitions
rmajette on DSK8KYBLC1PROD with MISCELLANEOUS
For purposes of this announcement,
the following definitions apply:
Minority Populations—American
Indian or Alaska Native; Asian; Black or
African American; Hispanic or Latino;
and Native Hawaiian or Other Pacific
Islander (42 U.S.C. 300u–6, section 1707
of the Public Health Service Act, as
amended.)
Multicultural Partnerships—
Multicultural, multi-racial, and multiethnic entities comprising organizations
and individuals that have come together
for a common purpose and that function
independently on behalf of the
partnership’s members to address health
disparities within communities of color.
State and Territorial Office of
Minority Health—An entity formally
established by Executive Order, statute,
or a state health officer to improve the
health of racial and ethnic populations.
Systems Change—An effort to ensure
that the resources and infrastructure
necessary are available and accessible to
address minority health and health
disparities as well as the public health
and health care needs of the American
population in general. Structural and
functional components of the system
must also be present—components such
as information, data, and evaluation
capabilities; trained, motivated, and
culturally/linguistically appropriate
staff; and facilities, equipment, and
technologies appropriate for the needs
of public health/health care
professionals and the people they serve.
Dated: June 5, 2007.
Garth N. Graham,
Deputy Assistant Secretary for Minority
Health.
[FR Doc. 07–2893 Filed 6–8–07; 8:45 am]
BILLING CODE 4150–29–P
VerDate Mar<15>2010
12:15 Mar 07, 2011
Jkt 223001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
SUMMARY: Notice is hereby given that
the Office of Research Integrity (ORI)
and the Assistant Secretary for Health
have taken final action in the following
case:
Wei Jin, Colorado State University:
Based on an investigation conducted by
Colorado State University (CSU) and
additional analysis and information
obtained by the Office of Research
Integrity during its oversight review, the
U.S. Public Health Service (PHS) found
that Mr. Wei Jin, former doctoral
candidate, Department of Chemistry,
CSU, engaged in research misconduct in
research funded by National Cancer
Institutes (NCI), National Institutes of
Health (NIH), grant R01 CA85419.
Specifically, Mr. Jin falsified data/
results by claiming he had performed a
novel total synthesis of renieramycin G,
when in fact, he obtained renieramycin
G through a relatively simple reaction
sequence from renieramycin M, a
natural product that was a gift to the
laboratory and that had been isolated by
others from the Thai sponge. Mr. Jin
included the falsified data/results in:
• His research notebooks and other
records of his research;
• His dissertation, ‘‘Asymmetric total
synthesis of (¥)-Reineramycin G and
studies toward the total synthesis of
Ecteinascidin-743’’;
• A manuscript, Jin, W. & Williams,
R., ‘‘Asymmetric total synthesis of (¥)Renieramycin G,’’ accepted by the
Journal of the American Chemical
Society; and
• Supplemental information relative
to the manuscript to be published
online.
ORI has implemented the following
administrative actions for a period of
three (3) years, beginning on May 8,
2007:
(1) Mr. Jin is debarred from eligibility
for any contracting or subcontracting
with any agency of the United States
Government and from eligibility or
involvement in nonprocurement
programs of the United States
Government referred to as ‘‘covered
transactions’’ as defined in HHS’
implementation of OMB Guidelines to
Agencies on Government-wide
Debarment and Suspension at 2 CFR
Part 376, et seq.; and
(2) Mr. Jin is prohibited from serving
in any advisory capacity to PHS,
PO 00000
Frm 00068
Fmt 4703
Sfmt 4703
32123
including but not limited to service on
any PHS advisory committee, board,
and/or peer review committee, or as a
consultant.
FOR FURTHER INFORMATION CONTACT:
Director, Division of Investigative
Oversight, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8800.
John Dahlberg,
Acting Director, Office of Research Integrity.
[FR Doc. 07–2866 Filed 6–8–07; 8:45 am]
BILLING CODE 4150–31–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Request for Notification From Industry
Organizations Interested in
Participating in Selection Process for
Nonvoting Industry Representatives on
Food Safety Public Advisory
Committee and Request for
Nominations for Nonvoting Industry
Representatives on Food Safety Public
Advisory Committee
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is requesting that
any industry organizations interested in
participating in the selection of
nonvoting industry representatives to
serve on its Food Advisory Committee
for the Center for Food Safety and
Applied Nutrition (CFSAN) notify FDA
in writing. A nominee may either be
self-nominated or nominated by an
organization to serve as a nonvoting
industry representative. Nominations
will be accepted for current vacancies
effective with this notice.
DATES: Any industry organization
interested in participating in the
selection of an appropriate nonvoting
member to represent industry interests
must send a letter stating that interest to
the FDA by July 11, 2007, for vacancies
listed in this notice. Concurrently,
nomination materials for prospective
candidates should be sent to FDA by
July 11, 2007.
ADDRESSES: All letters of interest and
nominations should be submitted in
writing to Carolyn Jeletic (see FOR
FURTHER INFORMATION CONTACT).
FOR FURTHER INFORMATION CONTACT:
Carolyn Jeletic, Center for Food Safety
and Applied Nutrition; Office of
Regulations, Policy, and Social Sciences
(HFS–24); Food and Drug
Administration, 5100 Paint Branch
E:\ERIC\11JNN1.SGM
11JNN1
]]>Agencies
[Federal Register Volume 72, Number 111 (Monday, June 11, 2007)]
[Notices]
[Page 32123]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 07-2866]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the Office of Research Integrity
(ORI) and the Assistant Secretary for Health have taken final action in
the following case:
Wei Jin, Colorado State University: Based on an investigation
conducted by Colorado State University (CSU) and additional analysis
and information obtained by the Office of Research Integrity during its
oversight review, the U.S. Public Health Service (PHS) found that Mr.
Wei Jin, former doctoral candidate, Department of Chemistry, CSU,
engaged in research misconduct in research funded by National Cancer
Institutes (NCI), National Institutes of Health (NIH), grant R01
CA85419.
Specifically, Mr. Jin falsified data/results by claiming he had
performed a novel total synthesis of renieramycin G, when in fact, he
obtained renieramycin G through a relatively simple reaction sequence
from renieramycin M, a natural product that was a gift to the
laboratory and that had been isolated by others from the Thai sponge.
Mr. Jin included the falsified data/results in:
His research notebooks and other records of his research;
His dissertation, ``Asymmetric total synthesis of (-)-
Reineramycin G and studies toward the total synthesis of Ecteinascidin-
743'';
A manuscript, Jin, W. & Williams, R., ``Asymmetric total
synthesis of (-)-Renieramycin G,'' accepted by the Journal of the
American Chemical Society; and
Supplemental information relative to the manuscript to be
published online.
ORI has implemented the following administrative actions for a
period of three (3) years, beginning on May 8, 2007:
(1) Mr. Jin is debarred from eligibility for any contracting or
subcontracting with any agency of the United States Government and from
eligibility or involvement in nonprocurement programs of the United
States Government referred to as ``covered transactions'' as defined in
HHS' implementation of OMB Guidelines to Agencies on Government-wide
Debarment and Suspension at 2 CFR Part 376, et seq.; and
(2) Mr. Jin is prohibited from serving in any advisory capacity to
PHS, including but not limited to service on any PHS advisory
committee, board, and/or peer review committee, or as a consultant.
FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative
Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite
750, Rockville, MD 20852, (240) 453-8800.
John Dahlberg,
Acting Director, Office of Research Integrity.
[FR Doc. 07-2866 Filed 6-8-07; 8:45 am]
BILLING CODE 4150-31-M
